Literature DB >> 7996299

Clostridium difficile infection: a common clinical problem for the general internist.

G M Caputo1, M R Weitekamp, A E Bacon, C Whitener.   

Abstract

Considering the current wide use of antimicrobial agents, the general internist is commonly faced with the patient at risk for diarrhea due to C. difficile. The diagnosis should be considered for any patient with diarrhea who has received any type of antibiotic therapy in the preceding 4-6 weeks. Symptoms may range from a minor bout of diarrhea to fulminant and fatal colitis. Diagnosis usually requires demonstration of the toxin in stool; culture of the organism and fiberoptic endoscopy may play an adjunctive role in selected clinical settings. The ultimate goal in the treatment for C. difficile infection is to repopulate the normal colonic flora in the most efficacious manner. Minimally symptomatic patients may respond to discontinuing the offending antimicrobial agent or using nonspecific binding agents. Oral vancomycin continues to be the "gold standard" for specific treatment, while metronidazole therapy is considered the first-line agent for individuals with milder infection. Oral bacitracin shows promise, though large studies are lacking. Patients with multiple relapses of C. difficile diarrhea can be treated with prolonged courses of vancomycin or a combination of vancomycin and rifampin. Intensive care unit patients who are NPO have few therapeutic options besides intravenous administration of metronidazole and oral administration of vancomycin via clamped nasogastric tube. Preventive efforts are directed at cautious use of antibiotics and the use of vinyl gloves when caring for patients with known infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7996299     DOI: 10.1007/BF02599229

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  65 in total

Review 1.  Exacerbation of ulcerative colitis.

Authors:  D J Hermens; P B Miner
Journal:  Gastroenterology       Date:  1991-07       Impact factor: 22.682

2.  In vitro synergy studies with Clostridium difficile.

Authors:  A E Bacon; S McGrath; R Fekety; W J Holloway
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Clindamycin-associated colitis. A prospective study.

Authors:  F J Tedesco; R W Barton; D H Alpers
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

4.  Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.

Authors:  D Seal; S P Borriello; F Barclay; A Welch; M Piper; M Bonnycastle
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

5.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

6.  Treatment of antibiotic-associated enterocolitis with vancomycin.

Authors:  R Fekety; J Silva; J Armstrong; M Allo; R Browne; J Ebright; R Lusk; G Rifkin; R Toshniwal
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

7.  Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease.

Authors:  Y M Trnka; J T LaMont
Journal:  Gastroenterology       Date:  1981-04       Impact factor: 22.682

8.  Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.

Authors:  D Y Leung; C P Kelly; M Boguniewicz; C Pothoulakis; J T LaMont; A Flores
Journal:  J Pediatr       Date:  1991-04       Impact factor: 4.406

9.  Clostridium difficile in a pediatric outpatient population.

Authors:  D A Boenning; G R Fleisher; J M Campos; C W Hulkower; R W Quinlan
Journal:  Pediatr Infect Dis       Date:  1982 Sep-Oct

10.  Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission.

Authors:  S Johnson; D N Gerding; M M Olson; M D Weiler; R A Hughes; C R Clabots; L R Peterson
Journal:  Am J Med       Date:  1990-02       Impact factor: 4.965

View more
  3 in total

Review 1.  Drug-induced Clostridium difficile-associated disease.

Authors:  M L Job; N F Jacobs
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

2.  Clostridium difficile infection as a cause of severe sepsis.

Authors:  S E Lowenkron; J Waxner; P Khullar; J S Ilowite; M S Niederman; A M Fein
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

Review 3.  Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease.

Authors:  F Frost; G F Craun; R L Calderon
Journal:  Emerg Infect Dis       Date:  1998 Oct-Dec       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.